Holen Sie sich die Stockscreener-App
102.27
14.57%
-17.44
Handel nachbörslich:
102.63
0.36
+0.35%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt KMB?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$119.71
Offen:
$104.69
24-Stunden-Volumen:
36.70M
Relative Volume:
12.32
Marktkapitalisierung:
$33.93B
Einnahmen:
$18.08B
Nettoeinkommen (Verlust:
$1.81B
KGV:
17.32
EPS:
5.904
Netto-Cashflow:
$2.10B
1W Leistung:
-15.21%
1M Leistung:
-16.57%
6M Leistung:
-21.54%
1J Leistung:
-24.02%
1-Tages-Spanne:
$102.20
$106.41
1-Wochen-Bereich:
$102.20
$123.09
52-Wochen-Spanne:
$102.20
$150.45
Kimberly Clark Corp Stock (KMB) Company Profile
Firmenname
Kimberly Clark Corp
Sektor
Telefon
(972) 281-1200
Adresse
351 PHELPS DRIVE, IRVING, TX
Vergleichen Sie KMB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KMB
Kimberly Clark Corp
|
102.27 | 39.73B | 18.08B | 1.81B | 2.10B | 5.904 |
|
PG
Procter Gamble Co
|
148.02 | 351.37B | 84.93B | 16.86B | 14.94B | 6.8506 |
|
UL
Unilever Plc Adr
|
60.67 | 147.58B | 64.99B | 6.71B | 6.53B | 2.4355 |
|
CL
Colgate Palmolive Co
|
74.98 | 62.11B | 20.10B | 3.04B | 3.37B | 3.569 |
|
KVUE
Kenvue Inc
|
16.14 | 27.58B | 15.14B | 1.42B | 1.63B | 0.7361 |
Kimberly Clark Corp Stock (KMB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-04 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2025-07-18 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-01-08 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-07-23 | Eingeleitet | TD Cowen | Buy |
| 2024-06-24 | Eingeleitet | Exane BNP Paribas | Neutral |
| 2024-06-13 | Hochstufung | BofA Securities | Underperform → Buy |
| 2024-06-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-28 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-03-01 | Fortgesetzt | Goldman | Buy |
| 2023-12-15 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-11-17 | Eingeleitet | Piper Sandler | Overweight |
| 2023-10-12 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-09-22 | Eingeleitet | HSBC Securities | Hold |
| 2023-03-20 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2023-02-17 | Eingeleitet | Citigroup | Sell |
| 2023-01-04 | Herabstufung | Jefferies | Buy → Hold |
| 2022-12-06 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2022-10-18 | Eingeleitet | Evercore ISI | In-line |
| 2022-10-12 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2022-09-14 | Fortgesetzt | BofA Securities | Neutral |
| 2022-02-02 | Herabstufung | Bernstein | Mkt Perform → Underperform |
| 2022-01-27 | Bestätigt | Citigroup | Sell |
| 2022-01-27 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-01-27 | Bestätigt | UBS | Neutral |
| 2022-01-27 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-11 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2021-10-26 | Herabstufung | Berenberg | Buy → Hold |
| 2021-09-09 | Eingeleitet | HSBC Securities | Hold |
| 2021-06-24 | Eingeleitet | UBS | Neutral |
| 2021-05-14 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2021-03-19 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-01-26 | Herabstufung | Argus | Buy → Hold |
| 2021-01-20 | Eingeleitet | Bernstein | Mkt Perform |
| 2020-12-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-10-16 | Eingeleitet | Berenberg | Buy |
| 2020-10-16 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-03-30 | Hochstufung | Jefferies | Hold → Buy |
| 2019-10-23 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2019-09-27 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-09-23 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-07-24 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2019-06-19 | Bestätigt | BofA/Merrill | Neutral |
| 2019-04-23 | Hochstufung | Argus | Hold → Buy |
| 2019-04-23 | Hochstufung | Macquarie | Neutral → Outperform |
| 2019-02-11 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2019-01-24 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2019-01-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-10-08 | Herabstufung | Goldman | Buy → Neutral |
| 2018-09-20 | Eingeleitet | Atlantic Equities | Underweight |
| 2018-08-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2018-08-15 | Herabstufung | Societe Generale | Buy → Hold |
| 2018-06-21 | Eingeleitet | Morgan Stanley | Underweight |
| 2017-12-14 | Eingeleitet | Deutsche Bank | Hold |
Alle ansehen
Kimberly Clark Corp Aktie (KMB) Neueste Nachrichten
Kimberly-Clark is taking Tylenol in $49 billion deal - Morning Brew
Kenvue’s Tylenol Litigation Overhang Doesn’t Dim ‘Generational Opportunity’ For Kimberly-Clark - Citeline News & Insights
Will Kimberly Clark Corporation stock outperform Dow Jones index2025 Short Interest & Fast Gaining Stock Reports - newser.com
Latham Advises on Financing for Kimberly-Clark’s Acquisition of Kenvue to Create a US$32 Billion Global Health and Wellness Leader - Legal Desire Media and Insights
The CEO Behind Kimberly-Clark’s $40 Billion Gamble on Tylenol Maker - The Wall Street Journal
Palantir, Kimberly-Clark, Hims & Hers, Navitas And Cipher Mining: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Kimberly-Clark to buy Kenvue in US$48.7 billion deal - Marketing-Interactive
Kimberly-Clark, Eaton Put Dealmakers on Cusp of $4 Trillion - Bloomberg.com
Kimberly-Clark Bets $50 Billion On Health And Beauty With Kenvue Deal - Finimize
Kimberly-Clark buys Kenvue; combined company expected to generate $32-billion a year - Yahoo News Canada
Kimberly-Clark to Acquire Kenvue - WWD
North Texas’ Kimberly-Clark To Acquire Tylenol Maker in $40B Deal - Dallas Innovates
Kimberly-Clark to Acquire Kenvue in $48.7 Billion Deal - BeautyMatter
Kimberly-Clark "considered all risks" before Tylenol deal - Axios
Kenvue’s legal risks loom over planned acquisition by Kimberly-Clark - Reuters
With Acquisition, Kimberly-Clark Bets That Tylenol Can Weather the Storm - The New York Times
Kimberly-Clark acquires Neutrogena-owner Kenvue - us.fashionnetwork.com
Kimberly-Clark Strikes $40 Billion Deal for Tylenol Maker Kenvue - The Wall Street Journal
Kimberly-Clark’s $50 billion leap into health and beauty tests investor faith - Reuters
Kimberly-Clark’s $50 billion leap into health and beauty tests investor faith By Reuters - Investing.com
Kenvue: Takeover by Kimberly-Clark Gives Shareholders a Lifeline - Morningstar
Kimberly-Clark Confirms Kenvue Acquisition Deal: Why It Is Buying the Tylenol Maker - International Business Times
Reports of ‘Click-to-Cancel’s Death May Be Premature - PYMNTS.com
Tylenol, Kleenex, Band-Aid and more put under one roof in $48.7 billion consumer brands deal - WTOP
S&P 500 Gains & Losses Today: Amazon Stock Jumps After OpenAI Deal; Kimberly-Clark Acquires Kenvue - Investopedia
U.S. Indexes Closed Mixed Monday As Lumen Technologies Led, Kimberly-Clark Lagged - Barron's
Options Corner: Kimberly-Clark's Implosion Offers An Unusual Informational Arbitrage Opportunity - Benzinga
Kimberly-Clark acquires Kenvue in $48.7 billion deal - lesprom.com
Kimberly-Clark to Buy Tylenol Maker Kenvue. Why KMB Stock Is Tanking. - Barron's
That $40 Billion Tylenol Deal Is Both Cheap and Risky - Bloomberg.com
Kimberly-Clark to Buy Tylenol Maker Kenvue for $40 Billion - Bloomberg.com
The Key Question Around The Kenvue/Kimberly-Clark Tie-Up (NYSE:KVUE) - Seeking Alpha
Kimberly-Clark to buy Tylenol maker Kenvue in landmark $40bn merger - The Guardian
Kimberly-Clark Corporation - Britannica
Kimberly-Clark bets $40 billion for Kenvue despite Tylenol controversy - Reuters
Kimberly-Clark buying Tylenol-maker Kenvue in cash, stock deal worth about $48.7B - ABC7 Los Angeles
Irving-based Kimberly-Clark buys Tylenol maker Kenvue in $48.7 billion deal - Dallas News
Why Kimberly-Clark and Tylenol are trending - CNN
Kimberly-Clark to Acquire Kenvue for $48.7 Billion - Pharmaceutical Executive
Kimberly-Clark buys Tylenol-maker Kenvue in $48.7 billion deal - The Spokesman-Review
Kenvue Stock Pops on News Kimberly-Clark Will Buy It for $48.7B. Is It Too Late to Buy KVUE Here? - Yahoo Finance
Kimberly-Clark, parent company of Kleenex and Huggies, buys the maker of Tylenol in $48.7 billion deal. What you need to know - Yahoo Finance
Kimberly-Clark makes a $49 billion bet that Tylenol risk is overblown - Yahoo Finance
Kimberly-Clark to Acquire Kenvue in $48.7B Mega Deal - USA Herald
Kimberly-Clark to buy Tylenol maker Kenvue in massive consumer merger - Yahoo Finance
Kenvue Shares Soar 16% After Inking $48.7B Deal With Kimberly-Clark - Stocktwits
Kimberly-Clark risks migraine with Kenvue deal - Financial Times
Kimberly-Clark Buys Summit-Based Kenvue in $48.7B Transaction - TAPinto
Kimberly-Clark to Acquire Tylenol Maker Kenvue in $49 Billion Deal - D Magazine
Kimberly-Clark to Acquire Kenvue in US$48.7 Billion Merger - Mexico Business News
What is Kenvue? What to know about the maker of Tylenol acquired by Kimberly-Clark - Dallas News
Finanzdaten der Kimberly Clark Corp-Aktie (KMB)
Umsatz
Nettogewinn
Free Cashflow
ENV
12.32%
3.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):